Nicholas A. Vitanza

Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute

Affiliated withSeattle Children’s Research Institute University of Washington

Research Area

Biography

Nicholas A. Vitanza has not added Biography.
If you are Nicholas A. Vitanza and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 7	2023

Other Publications

Article	Year
Immunotherapy for brain tumors: understanding early successes and limitations. Expert review of neurotherapeutics\| PubMed ID: 29322843	2018
Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-oncology\| PubMed ID: 30169876	2019
Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials. Current treatment options in neurology\| PubMed ID: 31290035	2019
EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget\| PubMed ID: 31903167	2019
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. Journal of neuro-oncology\| PubMed ID: 32556862	2020
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. Neuro-oncology\| PubMed ID: 33130903	2021
Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert review of neurotherapeutics\| PubMed ID: 33225764	2021
MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. Neuro-oncology advances\| PubMed ID: 33977272	2021
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature medicine\| PubMed ID: 34253928	2021
Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. Oncogene\| PubMed ID: 34759345	2022
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. Neuro-oncology advances\| PubMed ID: 34988452	2021
Two cases of pineal anlage tumor with molecular analysis. Pediatric blood & cancer\| PubMed ID: 35129878	2022
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro-oncology\| PubMed ID: 35137228	2022
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro-oncology\| PubMed ID: 35157764	2022
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro-oncology\| PubMed ID: 35481923	2022
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer discovery\| PubMed ID: 36259971	2023
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neuro-oncology advances\| PubMed ID: 36382108	2022
Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia (New York, N.Y.)\| PubMed ID: 36599192	2023
Functional genomic analysis of adult and pediatric brain tumor isolates. bioRxiv : the preprint server for biology\| PubMed ID: 36711964	2023